A groundbreaking study published in the Journal of Molecular Diagnostics reports the successful clinical validation of SeekInCare®, a novel, non-invasive multi-omics blood test designed for the early detection of multiple cancer types. Developed by researchers at SeekIn Inc., SeekInCare integrates advanced genomic, epigenetic, and proteomic analyses to identify cancer at its early stage, offering hope for improved outcomes through earlier intervention.
Key Findings
- Comprehensive Cancer Detection: SeekInCare leverages shallow whole-genome sequencing of cell-free DNA (cfDNA) and measures seven protein tumor markers from 8ml peripheral blood. The test analyzes multiple cancer hallmarks, including copy number aberration, fragment size, end motif, and oncogenic virus, combined with artificial intelligence algorithms to distinguish cancer patients from non-cancer individuals and predict the likely tissue of origin.
- Robust Clinical Validation: In a retrospective study involving 617 cancer patients (across 27 cancer types) and 580 non-cancer individuals, SeekInCare achieved a sensitivity of 60.0% at 98.3% specificity, with an area under the curve (AUC) of 0.899. Sensitivities increased with cancer stage: 37.7% (stage I), 50.4% (stage II), 66.7% (stage III), and 78.1% (stage IV).
- Real-World Evidence: The test was further validated in a prospective cohort of 1,203 individuals, achieving 70.0% sensitivity at 95.2% specificity over a median follow-up of 753 days.
- Comparable to Leading Tests: SeekInCare’s performance is on par with other multi-cancer early detection (MCED) tests currently in development, demonstrating its potential as a valuable tool for population-level cancer screening, especially in high-risk groups.
